A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study
暂无分享,去创建一个
C. Baufreton | J. D. de Brux | P. Binuani | P. Treanor | J. Corbeau | J. B. Subayi | J. C. Daniel | J. Subayi
[1] I. Shapira,et al. Protamine cardiotoxicity and nitric oxide. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[2] K. Kawazoe,et al. Reduction of heparin dose is not beneficial to platelet function. , 2000, The Annals of thoracic surgery.
[3] W. van Oeveren,et al. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. , 1999, Chest.
[4] H. Kojima,et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. , 1999, The Journal of thoracic and cardiovascular surgery.
[5] R. Salamon,et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[6] W. van Oeveren,et al. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? , 1999, The Annals of thoracic surgery.
[7] L. Shore-lesserson,et al. Pro: heparin-bonded circuits represent a desirable option for cardiopulmonary bypass. , 1998, Journal of cardiothoracic and vascular anesthesia.
[8] C. B. Mahoney. Heparin-bonded circuits: clinical outcomes and costs , 1998, Perfusion.
[9] R. Shemin,et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. , 1998, The Annals of thoracic surgery.
[10] B. Vollmar,et al. Enhancement of the leukocyte-endothelial cell interaction in collecting venules of skeletal muscle by protamine. , 1997, The Journal of thoracic and cardiovascular surgery.
[11] D. Kuik,et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[12] S. Bannan,et al. Low heparinization with heparin-bonded bypass circuits: is it a safe strategy? , 1997, The Annals of thoracic surgery.
[13] C. Baufreton,et al. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery. , 1996, ASAIO journal.
[14] H. O. Oudemans-van Straaten,et al. Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. , 1995, The Journal of thoracic and cardiovascular surgery.
[15] P. Bezemer,et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. , 1995, The Journal of thoracic and cardiovascular surgery.
[16] P. Everts,et al. Systemic blood activation with open and closed venous reservoirs. , 1995, The Annals of thoracic surgery.
[17] L. Greenfield,et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. , 1994, The Journal of thoracic and cardiovascular surgery.
[18] S. Westaby. Aprotinin in perspective. , 1993, The Annals of thoracic surgery.
[19] E. Blackstone,et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.
[20] C. Baufreton,et al. Heparin coating with aprotinin reduces blood activation during coronary artery operations. , 1997, The Annals of thoracic surgery.
[21] A. Galloway,et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. , 1995, The Annals of thoracic surgery.
[22] Z. Fishelson,et al. Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation. , 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.